Combined assessment ofKRASmutational status and tumor size has no impact on prognosis in early-stage non-small cell lung cancer

Abstract

Purpose: The aim of this study it to investigate the combined impact of KRAS mutational status and tumor size on overall survival and risk of death in stage I and II NSCLC. Methods: All consecutive patients molecularly assessed and diagnosed between 2016-2018 with stage I-II NSCLC in the region of West Sweden were included in this multi-center retrospective study. Primary study outcome was overall survival (OS) and risk of death (HR). Results: Out of 310 Stage I-II NSCLC patients, 37% harbored an activating mutation in the KRAS gene (KRASMUT). Our study confirmed staging and tumor size as prognostic factors. KRAS mutational status was not found to impact overall survival and no difference in risk of death was observed when combining KRAS mutational status and primary tumor size. Conclusions: KRAS mutations in combination with primary tumor size are not associated with a worse prognosis in stage I and II NSCLC.